A genomic approach to predict synergistic combinations for breast cancer treatment

We leverage genomic and biochemical data to identify synergistic drug regimens for breast cancer. In order to study the mechanism of the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) in breast cancer, we generated and validated genomic profiles...

Descripción completa

Detalles Bibliográficos
Autores principales: Soldi, Raffaella, Cohen, Adam L, Cheng, Luis, Sun, Ying, Moos, Philip, Bild, Andrea H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450767/
https://www.ncbi.nlm.nih.gov/pubmed/22083351
http://dx.doi.org/10.1038/tpj.2011.48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450767/
https://www.ncbi.nlm.nih.gov/pubmed/22083351
http://dx.doi.org/10.1038/tpj.2011.48

Ejemplares similares